ATP citrate lyase (ACL) inhibitor (IC50
= 0.13 μ
M for human recombinant ACL); blocks lipid synthesis (IC50
= 8 μ
M in HepG2 cells). Displays no cytotoxicity up to a concentration of 50 μ
M. Lowers plasma glucose and triglycerides in a mouse model of hyperlipidemia. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
Li et al.
A novel direct homogeneous assay for ATP citrate lyase.
Ma et al.
J.Lipid Res., 2009;50:2131